{"congress":"ESMO2025","meeting_name":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"total_abstracts":2343,"filtered":500,"offset":0,"limit":50,"has_more":true,"abstracts":[{"abstract_id":"2025-TPS8000","abstract_number":"TPS8000","doi":"10.1200/JCO.2025.44.17_suppl.TPS8000","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Trials in Progress Poster Session","title":"Trials in Progress Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"19:45","room":"Arie Crown Theater"},"title":"Quality of life outcomes with Opdivo in patients with NSCLC","authors":[{"name":"S. Antonia","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"E. Winer","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"J. Cortes","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"G. Curigliano","affiliation":"University of Chicago","is_presenter":false},{"name":"J. Brahmer","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-83","nct_id":"NCT42639282","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":23.5,"unit":"months","hr":0.89,"hr_ci95":[0.8,0.98],"p":"0.03"},{"name":"PFS","value":8.4,"unit":"months","hr":0.86,"hr_ci95":[0.78,0.99],"p":"0.03"},{"name":"ORR","value":52.6,"unit":"percent"}],"summary":"Median OS 23.5 months. HR 0.89 (95% CI 0.8–0.98). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-05T19:45:00-05:00","status":"released"}},{"abstract_id":"2025-9354","abstract_number":"9354","doi":"10.1200/JCO.2025.44.17_suppl.9354","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"19:45","room":"S406"},"title":"Quality of life outcomes with Keytruda in patients with NSCLC","authors":[{"name":"L. Paz-Ares","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"M. Reck","affiliation":"Chinese University of Hong Kong","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-965","nct_id":"NCT69593054","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":25.4,"unit":"months","hr":0.67,"hr_ci95":[0.57,0.77],"p":"0.08"},{"name":"PFS","value":11.7,"unit":"months","hr":0.64,"hr_ci95":[0.61,0.74],"p":"0.08"},{"name":"ORR","value":62.5,"unit":"percent"}],"summary":"Median OS 25.4 months. HR 0.67 (95% CI 0.57–0.77). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-05T19:45:00-05:00","status":"released"}},{"abstract_id":"2025-9362","abstract_number":"9362","doi":"10.1200/JCO.2025.44.17_suppl.9362","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Clinical Science Symposium","title":"Clinical Science Symposium: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"21:00","room":"S406"},"title":"Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-1","authors":[{"name":"J. Brahmer","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"M. Reck","affiliation":"Dana-Farber Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-1","nct_id":"NCT47188437","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":28.5,"unit":"months","hr":0.79,"hr_ci95":[0.65,0.93],"p":"0.002"},{"name":"PFS","value":10.6,"unit":"months","hr":0.75,"hr_ci95":[0.65,0.95],"p":"0.002"},{"name":"ORR","value":64,"unit":"percent"}],"summary":"Median OS 28.5 months. HR 0.79 (95% CI 0.65–0.93). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-02T21:00:00-05:00","status":"released"}},{"abstract_id":"2025-9807","abstract_number":"9807","doi":"10.1200/JCO.2025.44.17_suppl.9807","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"13:00","room":"Hall B1"},"title":"Real-world effectiveness of Opdivo vs standard of care in NSCLC","authors":[{"name":"S. Tolaney","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"N. Rizvi","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"C. Saura","affiliation":"Princess Margaret Cancer Centre","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-851","nct_id":"NCT03723917","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":18.1,"unit":"months","hr":0.86,"hr_ci95":[0.75,0.97],"p":"0.08"},{"name":"PFS","value":7.3,"unit":"months","hr":0.84,"hr_ci95":[0.76,0.95],"p":"0.08"},{"name":"ORR","value":48.7,"unit":"percent"}],"summary":"Median OS 18.1 months. HR 0.86 (95% CI 0.75–0.97). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-02T13:00:00-05:00","status":"released"}},{"abstract_id":"2025-9409","abstract_number":"9409","doi":"10.1200/JCO.2025.44.17_suppl.9409","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"16:30","room":"E450"},"title":"FLAURA-100: Tagrisso (osimertinib) 3L+ in NSCLC","authors":[{"name":"J. Brahmer","affiliation":"Cleveland Clinic","is_presenter":true},{"name":"S. Peters","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"C. Saura","affiliation":"University of Chicago","is_presenter":false},{"name":"G. Curigliano","affiliation":"National Cancer Center Japan","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-100","nct_id":"NCT98398336","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"standard of care","endpoints":[{"name":"OS","value":19.2,"unit":"months","hr":0.66,"hr_ci95":[0.52,0.8],"p":"0.08"},{"name":"PFS","value":11.8,"unit":"months","hr":0.71,"hr_ci95":[0.52,0.77],"p":"0.08"},{"name":"ORR","value":50.4,"unit":"percent"}],"summary":"Median OS 19.2 months. HR 0.66 (95% CI 0.52–0.8). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-03T16:30:00-05:00","status":"released"}},{"abstract_id":"2025-9872","abstract_number":"9872","doi":"10.1200/JCO.2025.44.17_suppl.9872","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-01","time_local":"15:15","room":"S100A"},"title":"Quality of life outcomes with Tagrisso in patients with NSCLC","authors":[{"name":"J. Cortes","affiliation":"Chinese University of Hong Kong","is_presenter":true},{"name":"M. Reck","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"S. Tolaney","affiliation":"Mayo Clinic","is_presenter":false},{"name":"S. Modi","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-585","nct_id":"NCT30595720","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"standard of care","endpoints":[{"name":"OS","value":26.2,"unit":"months","hr":0.8,"hr_ci95":[0.71,0.89],"p":"0.03"},{"name":"PFS","value":11.8,"unit":"months","hr":0.82,"hr_ci95":[0.68,0.91],"p":"0.03"},{"name":"ORR","value":62.3,"unit":"percent"}],"summary":"Median OS 26.2 months. HR 0.8 (95% CI 0.71–0.89). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-01T15:15:00-05:00","status":"released"}},{"abstract_id":"2025-9778","abstract_number":"9778","doi":"10.1200/JCO.2025.44.17_suppl.9778","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"21:30","room":"Arie Crown Theater"},"title":"Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-549","authors":[{"name":"A. Spira","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"M. Krop","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"S. Modi","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"J. Cortes","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"N. Rizvi","affiliation":"Princess Margaret Cancer Centre","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-549","nct_id":"NCT02925015","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":26.4,"unit":"months","hr":0.6,"hr_ci95":[0.49,0.71],"p":"0.08"},{"name":"PFS","value":7.9,"unit":"months","hr":0.55,"hr_ci95":[0.45,0.7],"p":"0.08"},{"name":"ORR","value":60.1,"unit":"percent"}],"summary":"Median OS 26.4 months. HR 0.6 (95% CI 0.49–0.71). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-04T21:30:00-05:00","status":"released"}},{"abstract_id":"2025-LBA4007","abstract_number":"LBA4007","doi":"10.1200/JCO.2025.44.17_suppl.LBA4007","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Late-Breaking Oral Abstract Session","title":"Late-Breaking Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"16:00","room":"E450"},"title":"Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-752 study)","authors":[{"name":"S. Modi","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"M. Krop","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"J. Brahmer","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-752","nct_id":"NCT14722173","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":23.4,"unit":"months","hr":0.83,"hr_ci95":[0.73,0.93],"p":"0.08"},{"name":"PFS","value":10.6,"unit":"months","hr":0.8,"hr_ci95":[0.76,0.89],"p":"0.08"},{"name":"ORR","value":54.6,"unit":"percent"}],"summary":"Median OS 23.4 months. HR 0.83 (95% CI 0.73–0.93). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-02T16:00:00-05:00","status":"released"}},{"abstract_id":"2025-TPS8008","abstract_number":"TPS8008","doi":"10.1200/JCO.2025.44.17_suppl.TPS8008","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Trials in Progress Poster Session","title":"Trials in Progress Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"21:00","room":"Arie Crown Theater"},"title":"Real-world effectiveness of Enhertu vs standard of care in NSCLC","authors":[{"name":"H. Rugo","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"P. Schmid","affiliation":"Cleveland Clinic","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-252","nct_id":"NCT19699607","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":16.9,"unit":"months","hr":0.58,"hr_ci95":[0.48,0.68],"p":"0.03"},{"name":"PFS","value":10.2,"unit":"months","hr":0.6,"hr_ci95":[0.49,0.64],"p":"0.03"},{"name":"ORR","value":57,"unit":"percent"}],"summary":"Median OS 16.9 months. HR 0.58 (95% CI 0.48–0.68). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-04T21:00:00-05:00","status":"released"}},{"abstract_id":"2025-9338","abstract_number":"9338","doi":"10.1200/JCO.2025.44.17_suppl.9338","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-01","time_local":"19:45","room":"E450"},"title":"Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-571 study)","authors":[{"name":"L. Paz-Ares","affiliation":"Karolinska Institute","is_presenter":true},{"name":"P. Schmid","affiliation":"Cleveland Clinic","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-571","nct_id":"NCT49078265","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":20.2,"unit":"months","hr":0.82,"hr_ci95":[0.74,0.9],"p":"0.03"},{"name":"PFS","value":7.1,"unit":"months","hr":0.84,"hr_ci95":[0.71,0.92],"p":"0.03"},{"name":"ORR","value":58.2,"unit":"percent"}],"summary":"Median OS 20.2 months. HR 0.82 (95% CI 0.74–0.9). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-01T19:45:00-05:00","status":"released"}},{"abstract_id":"2025-9170","abstract_number":"9170","doi":"10.1200/JCO.2025.44.17_suppl.9170","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"16:45","room":"S406"},"title":"Real-world effectiveness of Keytruda vs standard of care in NSCLC","authors":[{"name":"S. Peters","affiliation":"Karolinska Institute","is_presenter":true},{"name":"S. Tolaney","affiliation":"Mayo Clinic","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-599","nct_id":"NCT35199896","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":26.8,"unit":"months","hr":0.71,"hr_ci95":[0.58,0.84],"p":"0.002"},{"name":"PFS","value":7.3,"unit":"months","hr":0.66,"hr_ci95":[0.61,0.84],"p":"0.002"},{"name":"ORR","value":53.5,"unit":"percent"}],"summary":"Median OS 26.8 months. HR 0.71 (95% CI 0.58–0.84). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-03T16:45:00-05:00","status":"released"}},{"abstract_id":"2025-9557","abstract_number":"9557","doi":"10.1200/JCO.2025.44.17_suppl.9557","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"14:45","room":"S406"},"title":"Real-world effectiveness of Imfinzi vs standard of care in NSCLC","authors":[{"name":"S. Modi","affiliation":"University of Chicago","is_presenter":true},{"name":"P. Schmid","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"H. Rugo","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"H. Borghaei","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"N. Rizvi","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-8","nct_id":"NCT09964882","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":23.9,"unit":"months","hr":0.58,"hr_ci95":[0.44,0.72],"p":"0.03"},{"name":"PFS","value":8.8,"unit":"months","hr":0.6,"hr_ci95":[0.41,0.73],"p":"0.03"},{"name":"ORR","value":55,"unit":"percent"}],"summary":"Median OS 23.9 months. HR 0.58 (95% CI 0.44–0.72). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-02T14:45:00-05:00","status":"released"}},{"abstract_id":"2025-9738","abstract_number":"9738","doi":"10.1200/JCO.2025.44.17_suppl.9738","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-01","time_local":"20:45","room":"Hall B1"},"title":"Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-673","authors":[{"name":"M.C. Garassino","affiliation":"Karolinska Institute","is_presenter":true},{"name":"M. Krop","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"S. Antonia","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-673","nct_id":"NCT55306865","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":30,"unit":"months","hr":0.77,"hr_ci95":[0.66,0.88],"p":"0.08"},{"name":"PFS","value":10.2,"unit":"months","hr":0.79,"hr_ci95":[0.63,0.88],"p":"0.08"},{"name":"ORR","value":47.6,"unit":"percent"}],"summary":"Median OS 30 months. HR 0.77 (95% CI 0.66–0.88). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-01T20:45:00-05:00","status":"released"}},{"abstract_id":"2025-9502","abstract_number":"9502","doi":"10.1200/JCO.2025.44.17_suppl.9502","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"14:30","room":"E450"},"title":"Long-term follow-up of Tecentriq maintenance for NSCLC: IMpower-634","authors":[{"name":"E. Winer","affiliation":"Chinese University of Hong Kong","is_presenter":true},{"name":"S. Tolaney","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"P. Schmid","affiliation":"Karolinska Institute","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-634","nct_id":"NCT33524464","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":25.4,"unit":"months","hr":0.56,"hr_ci95":[0.47,0.65],"p":"<0.001"},{"name":"PFS","value":8,"unit":"months","hr":0.54,"hr_ci95":[0.46,0.69],"p":"<0.001"},{"name":"ORR","value":55.1,"unit":"percent"}],"summary":"Median OS 25.4 months. HR 0.56 (95% CI 0.47–0.65). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-05T14:30:00-05:00","status":"released"}},{"abstract_id":"2025-9273","abstract_number":"9273","doi":"10.1200/JCO.2025.44.17_suppl.9273","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"21:15","room":"Hall B1"},"title":"Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-350 study)","authors":[{"name":"M.C. Garassino","affiliation":"Cleveland Clinic","is_presenter":true},{"name":"E. Winer","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"M. Reck","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"N. Rizvi","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"A. Spira","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-350","nct_id":"NCT10018514","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"standard of care","endpoints":[{"name":"OS","value":19.6,"unit":"months","hr":0.79,"hr_ci95":[0.66,0.92],"p":"0.002"},{"name":"PFS","value":7.6,"unit":"months","hr":0.8,"hr_ci95":[0.66,0.89],"p":"0.002"},{"name":"ORR","value":57.5,"unit":"percent"}],"summary":"Median OS 19.6 months. HR 0.79 (95% CI 0.66–0.92). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-03T21:15:00-05:00","status":"released"}},{"abstract_id":"2025-9329","abstract_number":"9329","doi":"10.1200/JCO.2025.44.17_suppl.9329","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Clinical Science Symposium","title":"Clinical Science Symposium: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"20:00","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-694","authors":[{"name":"M. Krop","affiliation":"Chinese University of Hong Kong","is_presenter":true},{"name":"F. Andre","affiliation":"Mayo Clinic","is_presenter":false},{"name":"S. Tolaney","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"R. Herbst","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-694","nct_id":"NCT07441749","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":18,"unit":"months","hr":0.63,"hr_ci95":[0.52,0.74],"p":"0.002"},{"name":"PFS","value":11.2,"unit":"months","hr":0.59,"hr_ci95":[0.49,0.76],"p":"0.002"},{"name":"ORR","value":56.2,"unit":"percent"}],"summary":"Median OS 18 months. HR 0.63 (95% CI 0.52–0.74). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-03T20:00:00-05:00","status":"released"}},{"abstract_id":"2025-9330","abstract_number":"9330","doi":"10.1200/JCO.2025.44.17_suppl.9330","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Rapid Oral Abstract Session","title":"Rapid Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"18:30","room":"E450"},"title":"Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-642 study)","authors":[{"name":"A. Spira","affiliation":"MD Anderson Cancer Center","is_presenter":true},{"name":"S. Peters","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"J. Cortes","affiliation":"Karolinska Institute","is_presenter":false},{"name":"S. Tolaney","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"M.C. Garassino","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-642","nct_id":"NCT75915131","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":16.5,"unit":"months","hr":0.79,"hr_ci95":[0.7,0.88],"p":"0.03"},{"name":"PFS","value":9.6,"unit":"months","hr":0.78,"hr_ci95":[0.68,0.9],"p":"0.03"},{"name":"ORR","value":61.8,"unit":"percent"}],"summary":"Median OS 16.5 months. HR 0.79 (95% CI 0.7–0.88). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-05T18:30:00-05:00","status":"released"}},{"abstract_id":"2025-9263","abstract_number":"9263","doi":"10.1200/JCO.2025.44.17_suppl.9263","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-01","time_local":"16:30","room":"S406"},"title":"Real-world effectiveness of Tecentriq vs standard of care in NSCLC","authors":[{"name":"H. Borghaei","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"T. Mok","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"E. Winer","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"S. Peters","affiliation":"Massachusetts General Hospital","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-550","nct_id":"NCT68840737","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":24.1,"unit":"months","hr":0.9,"hr_ci95":[0.79,0.99],"p":"0.03"},{"name":"PFS","value":7.8,"unit":"months","hr":0.95,"hr_ci95":[0.78,0.96],"p":"0.03"},{"name":"ORR","value":55.2,"unit":"percent"}],"summary":"Median OS 24.1 months. HR 0.9 (95% CI 0.79–0.99). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-01T16:30:00-05:00","status":"released"}},{"abstract_id":"2025-9215","abstract_number":"9215","doi":"10.1200/JCO.2025.44.17_suppl.9215","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"15:15","room":"E450"},"title":"FLAURA-660: Tagrisso (osimertinib) neoadjuvant in NSCLC","authors":[{"name":"H. Rugo","affiliation":"University of Chicago","is_presenter":true},{"name":"H. Borghaei","affiliation":"Dana-Farber Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-660","nct_id":"NCT65841734","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":27.5,"unit":"months","hr":0.71,"hr_ci95":[0.59,0.83],"p":"<0.001"},{"name":"PFS","value":11.1,"unit":"months","hr":0.73,"hr_ci95":[0.63,0.84],"p":"<0.001"},{"name":"ORR","value":44.7,"unit":"percent"}],"summary":"Median OS 27.5 months. HR 0.71 (95% CI 0.59–0.83). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-05T15:15:00-05:00","status":"released"}},{"abstract_id":"2025-9641","abstract_number":"9641","doi":"10.1200/JCO.2025.44.17_suppl.9641","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"15:30","room":"Hall B1"},"title":"Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-936","authors":[{"name":"S. Modi","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"N. Rizvi","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-936","nct_id":"NCT35330998","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":21.2,"unit":"months","hr":0.75,"hr_ci95":[0.64,0.86],"p":"0.08"},{"name":"PFS","value":7.8,"unit":"months","hr":0.72,"hr_ci95":[0.67,0.86],"p":"0.08"},{"name":"ORR","value":49.9,"unit":"percent"}],"summary":"Median OS 21.2 months. HR 0.75 (95% CI 0.64–0.86). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-02T15:30:00-05:00","status":"released"}},{"abstract_id":"2025-9587","abstract_number":"9587","doi":"10.1200/JCO.2025.44.17_suppl.9587","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"19:00","room":"Hall B1"},"title":"Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-776","authors":[{"name":"P. Schmid","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"C. Robert","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"F. Andre","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"C. Saura","affiliation":"Massachusetts General Hospital","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-776","nct_id":"NCT42519762","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":18.5,"unit":"months","hr":0.89,"hr_ci95":[0.78,0.99],"p":"0.08"},{"name":"PFS","value":11.3,"unit":"months","hr":0.88,"hr_ci95":[0.76,0.99],"p":"0.08"},{"name":"ORR","value":54.6,"unit":"percent"}],"summary":"Median OS 18.5 months. HR 0.89 (95% CI 0.78–0.99). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-05T19:00:00-05:00","status":"released"}},{"abstract_id":"2025-9750","abstract_number":"9750","doi":"10.1200/JCO.2025.44.17_suppl.9750","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-01","time_local":"13:30","room":"Arie Crown Theater"},"title":"Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-251","authors":[{"name":"S. Peters","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"N. Rizvi","affiliation":"Chinese University of Hong Kong","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-251","nct_id":"NCT72483751","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":23.2,"unit":"months","hr":0.56,"hr_ci95":[0.46,0.66],"p":"<0.001"},{"name":"PFS","value":8.2,"unit":"months","hr":0.52,"hr_ci95":[0.42,0.62],"p":"<0.001"},{"name":"ORR","value":42.3,"unit":"percent"}],"summary":"Median OS 23.2 months. HR 0.56 (95% CI 0.46–0.66). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-01T13:30:00-05:00","status":"released"}},{"abstract_id":"2025-9343","abstract_number":"9343","doi":"10.1200/JCO.2025.44.17_suppl.9343","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"16:00","room":"Arie Crown Theater"},"title":"Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-54","authors":[{"name":"N. Rizvi","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"J. Brahmer","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"H. Rugo","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"C. Robert","affiliation":"Dana-Farber Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-54","nct_id":"NCT98203847","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":18.4,"unit":"months","hr":0.63,"hr_ci95":[0.53,0.73],"p":"0.08"},{"name":"PFS","value":7.7,"unit":"months","hr":0.64,"hr_ci95":[0.56,0.76],"p":"0.08"},{"name":"ORR","value":48.4,"unit":"percent"}],"summary":"Median OS 18.4 months. HR 0.63 (95% CI 0.53–0.73). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-03T16:00:00-05:00","status":"released"}},{"abstract_id":"2025-9752","abstract_number":"9752","doi":"10.1200/JCO.2025.44.17_suppl.9752","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"19:45","room":"Hall B1"},"title":"Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-485 study)","authors":[{"name":"H. Rugo","affiliation":"Mayo Clinic","is_presenter":true},{"name":"J. Brahmer","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-485","nct_id":"NCT51750589","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":29.1,"unit":"months","hr":0.6,"hr_ci95":[0.52,0.68],"p":"0.014"},{"name":"PFS","value":11.9,"unit":"months","hr":0.63,"hr_ci95":[0.56,0.69],"p":"0.014"},{"name":"ORR","value":61.1,"unit":"percent"}],"summary":"Median OS 29.1 months. HR 0.6 (95% CI 0.52–0.68). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-03T19:45:00-05:00","status":"released"}},{"abstract_id":"2025-9932","abstract_number":"9932","doi":"10.1200/JCO.2025.44.17_suppl.9932","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"15:30","room":"S406"},"title":"Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-42","authors":[{"name":"C. Robert","affiliation":"Karolinska Institute","is_presenter":true},{"name":"G. Curigliano","affiliation":"Dana-Farber Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-42","nct_id":"NCT87090579","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"standard of care","endpoints":[{"name":"OS","value":19.3,"unit":"months","hr":0.7,"hr_ci95":[0.58,0.82],"p":"<0.001"},{"name":"PFS","value":8.5,"unit":"months","hr":0.74,"hr_ci95":[0.58,0.81],"p":"<0.001"},{"name":"ORR","value":53.6,"unit":"percent"}],"summary":"Median OS 19.3 months. HR 0.7 (95% CI 0.58–0.82). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-03T15:30:00-05:00","status":"released"}},{"abstract_id":"2025-9624","abstract_number":"9624","doi":"10.1200/JCO.2025.44.17_suppl.9624","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"13:00","room":"Hall B1"},"title":"Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-422 study)","authors":[{"name":"T. Mok","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"L. Paz-Ares","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-422","nct_id":"NCT95840446","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":16.1,"unit":"months","hr":0.7,"hr_ci95":[0.6,0.8],"p":"<0.001"},{"name":"PFS","value":9.1,"unit":"months","hr":0.74,"hr_ci95":[0.61,0.82],"p":"<0.001"},{"name":"ORR","value":53.8,"unit":"percent"}],"summary":"Median OS 16.1 months. HR 0.7 (95% CI 0.6–0.8). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-04T13:00:00-05:00","status":"released"}},{"abstract_id":"2025-TPS8026","abstract_number":"TPS8026","doi":"10.1200/JCO.2025.44.17_suppl.TPS8026","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Trials in Progress Poster Session","title":"Trials in Progress Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"15:45","room":"S406"},"title":"Real-world effectiveness of Tagrisso vs standard of care in NSCLC","authors":[{"name":"L. Paz-Ares","affiliation":"MD Anderson Cancer Center","is_presenter":true},{"name":"A. Spira","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-563","nct_id":"NCT23965172","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":24.6,"unit":"months","hr":0.61,"hr_ci95":[0.5,0.72],"p":"0.014"},{"name":"PFS","value":8,"unit":"months","hr":0.65,"hr_ci95":[0.52,0.76],"p":"0.014"},{"name":"ORR","value":57.4,"unit":"percent"}],"summary":"Median OS 24.6 months. HR 0.61 (95% CI 0.5–0.72). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-04T15:45:00-05:00","status":"released"}},{"abstract_id":"2025-9753","abstract_number":"9753","doi":"10.1200/JCO.2025.44.17_suppl.9753","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"16:30","room":"Arie Crown Theater"},"title":"Quality of life outcomes with Tecentriq in patients with NSCLC","authors":[{"name":"A. Spira","affiliation":"Institut Gustave Roussy","is_presenter":true},{"name":"M. Krop","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"S. Modi","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"E. Winer","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"H. Rugo","affiliation":"Princess Margaret Cancer Centre","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-527","nct_id":"NCT66724580","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":21.6,"unit":"months","hr":0.57,"hr_ci95":[0.47,0.67],"p":"0.014"},{"name":"PFS","value":7.5,"unit":"months","hr":0.59,"hr_ci95":[0.5,0.64],"p":"0.014"},{"name":"ORR","value":43.9,"unit":"percent"}],"summary":"Median OS 21.6 months. HR 0.57 (95% CI 0.47–0.67). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-04T16:30:00-05:00","status":"released"}},{"abstract_id":"2025-9986","abstract_number":"9986","doi":"10.1200/JCO.2025.44.17_suppl.9986","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-01","time_local":"21:00","room":"S100A"},"title":"Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-718 study)","authors":[{"name":"S. Tolaney","affiliation":"University of Chicago","is_presenter":true},{"name":"H. Borghaei","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-718","nct_id":"NCT24055275","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":26.9,"unit":"months","hr":0.69,"hr_ci95":[0.57,0.81],"p":"0.08"},{"name":"PFS","value":9.3,"unit":"months","hr":0.72,"hr_ci95":[0.61,0.79],"p":"0.08"},{"name":"ORR","value":45.4,"unit":"percent"}],"summary":"Median OS 26.9 months. HR 0.69 (95% CI 0.57–0.81). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-01T21:00:00-05:00","status":"released"}},{"abstract_id":"2025-9957","abstract_number":"9957","doi":"10.1200/JCO.2025.44.17_suppl.9957","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"14:00","room":"E450"},"title":"Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-653 study)","authors":[{"name":"J. Brahmer","affiliation":"Dana-Farber Cancer Institute","is_presenter":true},{"name":"S. Antonia","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"C. Robert","affiliation":"Karolinska Institute","is_presenter":false},{"name":"H. Borghaei","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"T. Mok","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-653","nct_id":"NCT56560328","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":23.6,"unit":"months","hr":0.68,"hr_ci95":[0.6,0.76],"p":"0.014"},{"name":"PFS","value":9.6,"unit":"months","hr":0.72,"hr_ci95":[0.62,0.78],"p":"0.014"},{"name":"ORR","value":57.2,"unit":"percent"}],"summary":"Median OS 23.6 months. HR 0.68 (95% CI 0.6–0.76). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-04T14:00:00-05:00","status":"released"}},{"abstract_id":"2025-9180","abstract_number":"9180","doi":"10.1200/JCO.2025.44.17_suppl.9180","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"18:30","room":"Hall B1"},"title":"PACIFIC-282: Imfinzi (durvalumab) 3L+ in NSCLC","authors":[{"name":"E. Winer","affiliation":"MD Anderson Cancer Center","is_presenter":true},{"name":"S. Tolaney","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"R. Herbst","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-282","nct_id":"NCT10483888","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":29.5,"unit":"months","hr":0.67,"hr_ci95":[0.57,0.77],"p":"0.002"},{"name":"PFS","value":10,"unit":"months","hr":0.68,"hr_ci95":[0.6,0.77],"p":"0.002"},{"name":"ORR","value":44.9,"unit":"percent"}],"summary":"Median OS 29.5 months. HR 0.67 (95% CI 0.57–0.77). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-02T18:30:00-05:00","status":"released"}},{"abstract_id":"2025-9171","abstract_number":"9171","doi":"10.1200/JCO.2025.44.17_suppl.9171","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"19:00","room":"Hall B1"},"title":"Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-866 study)","authors":[{"name":"S. Modi","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"S. Tolaney","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"R. Herbst","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"P. Schmid","affiliation":"Chinese University of Hong Kong","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-866","nct_id":"NCT88668033","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":16.4,"unit":"months","hr":0.68,"hr_ci95":[0.58,0.78],"p":"0.014"},{"name":"PFS","value":10.4,"unit":"months","hr":0.64,"hr_ci95":[0.59,0.78],"p":"0.014"},{"name":"ORR","value":64.9,"unit":"percent"}],"summary":"Median OS 16.4 months. HR 0.68 (95% CI 0.58–0.78). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-05T19:00:00-05:00","status":"released"}},{"abstract_id":"2025-9071","abstract_number":"9071","doi":"10.1200/JCO.2025.44.17_suppl.9071","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"20:00","room":"S100A"},"title":"Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-105","authors":[{"name":"S. Peters","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"P. Schmid","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-105","nct_id":"NCT73270419","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":23.3,"unit":"months","hr":0.86,"hr_ci95":[0.74,0.98],"p":"0.08"},{"name":"PFS","value":7.3,"unit":"months","hr":0.82,"hr_ci95":[0.72,0.97],"p":"0.08"},{"name":"ORR","value":56.4,"unit":"percent"}],"summary":"Median OS 23.3 months. HR 0.86 (95% CI 0.74–0.98). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-02T20:00:00-05:00","status":"released"}},{"abstract_id":"2025-9310","abstract_number":"9310","doi":"10.1200/JCO.2025.44.17_suppl.9310","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-01","time_local":"15:30","room":"S100A"},"title":"Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-873","authors":[{"name":"R. Herbst","affiliation":"Institut Gustave Roussy","is_presenter":true},{"name":"S. Peters","affiliation":"Cleveland Clinic","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-873","nct_id":"NCT77486045","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":21.2,"unit":"months","hr":0.82,"hr_ci95":[0.72,0.92],"p":"0.08"},{"name":"PFS","value":8.5,"unit":"months","hr":0.8,"hr_ci95":[0.75,0.94],"p":"0.08"},{"name":"ORR","value":54.5,"unit":"percent"}],"summary":"Median OS 21.2 months. HR 0.82 (95% CI 0.72–0.92). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-01T15:30:00-05:00","status":"released"}},{"abstract_id":"2025-9659","abstract_number":"9659","doi":"10.1200/JCO.2025.44.17_suppl.9659","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"18:30","room":"Hall B1"},"title":"Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-527","authors":[{"name":"S. Antonia","affiliation":"Dana-Farber Cancer Institute","is_presenter":true},{"name":"S. Tolaney","affiliation":"Karolinska Institute","is_presenter":false},{"name":"G. Curigliano","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"M. Reck","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-527","nct_id":"NCT53665048","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":21.4,"unit":"months","hr":0.6,"hr_ci95":[0.48,0.72],"p":"<0.001"},{"name":"PFS","value":9.3,"unit":"months","hr":0.57,"hr_ci95":[0.47,0.72],"p":"<0.001"},{"name":"ORR","value":60.6,"unit":"percent"}],"summary":"Median OS 21.4 months. HR 0.6 (95% CI 0.48–0.72). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-04T18:30:00-05:00","status":"released"}},{"abstract_id":"2025-9199","abstract_number":"9199","doi":"10.1200/JCO.2025.44.17_suppl.9199","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"14:30","room":"Arie Crown Theater"},"title":"IMpower-809: Tecentriq (atezolizumab) 3L+ in NSCLC","authors":[{"name":"M. Krop","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"E. Winer","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"H. Borghaei","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"S. Peters","affiliation":"University of Chicago","is_presenter":false},{"name":"A. Spira","affiliation":"Princess Margaret Cancer Centre","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-809","nct_id":"NCT23037256","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":25.4,"unit":"months","hr":0.89,"hr_ci95":[0.77,0.99],"p":"0.002"},{"name":"PFS","value":9.2,"unit":"months","hr":0.87,"hr_ci95":[0.75,0.99],"p":"0.002"},{"name":"ORR","value":53.8,"unit":"percent"}],"summary":"Median OS 25.4 months. HR 0.89 (95% CI 0.77–0.99). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-05T14:30:00-05:00","status":"released"}},{"abstract_id":"2025-9517","abstract_number":"9517","doi":"10.1200/JCO.2025.44.17_suppl.9517","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Clinical Science Symposium","title":"Clinical Science Symposium: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"16:00","room":"Arie Crown Theater"},"title":"Quality of life outcomes with Enhertu in patients with NSCLC","authors":[{"name":"T. Mok","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"H. Borghaei","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-180","nct_id":"NCT11686724","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":21.7,"unit":"months","hr":0.71,"hr_ci95":[0.59,0.83],"p":"0.08"},{"name":"PFS","value":10.4,"unit":"months","hr":0.7,"hr_ci95":[0.55,0.83],"p":"0.08"},{"name":"ORR","value":61.2,"unit":"percent"}],"summary":"Median OS 21.7 months. HR 0.71 (95% CI 0.59–0.83). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-04T16:00:00-05:00","status":"released"}},{"abstract_id":"2025-9623","abstract_number":"9623","doi":"10.1200/JCO.2025.44.17_suppl.9623","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"20:45","room":"S100A"},"title":"Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-304 study)","authors":[{"name":"L. Paz-Ares","affiliation":"National Cancer Center Japan","is_presenter":true},{"name":"C. Saura","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-304","nct_id":"NCT19862340","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":18.1,"unit":"months","hr":0.85,"hr_ci95":[0.76,0.94],"p":"0.014"},{"name":"PFS","value":10.5,"unit":"months","hr":0.87,"hr_ci95":[0.8,0.92],"p":"0.014"},{"name":"ORR","value":54.3,"unit":"percent"}],"summary":"Median OS 18.1 months. HR 0.85 (95% CI 0.76–0.94). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-03T20:45:00-05:00","status":"released"}},{"abstract_id":"2025-9579","abstract_number":"9579","doi":"10.1200/JCO.2025.44.17_suppl.9579","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"14:15","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-728","authors":[{"name":"C. Saura","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"S. Peters","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"S. Modi","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"N. Rizvi","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-728","nct_id":"NCT16434258","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":24.5,"unit":"months","hr":0.56,"hr_ci95":[0.46,0.66],"p":"0.014"},{"name":"PFS","value":7.1,"unit":"months","hr":0.51,"hr_ci95":[0.49,0.69],"p":"0.014"},{"name":"ORR","value":55.6,"unit":"percent"}],"summary":"Median OS 24.5 months. HR 0.56 (95% CI 0.46–0.66). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-02T14:15:00-05:00","status":"released"}},{"abstract_id":"2025-9968","abstract_number":"9968","doi":"10.1200/JCO.2025.44.17_suppl.9968","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Rapid Oral Abstract Session","title":"Rapid Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"16:45","room":"E450"},"title":"Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-303 study)","authors":[{"name":"F. Andre","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"S. Peters","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"J. Cortes","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"C. Saura","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"H. Borghaei","affiliation":"Dana-Farber Cancer Institute","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-303","nct_id":"NCT65373527","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":18.3,"unit":"months","hr":0.6,"hr_ci95":[0.46,0.74],"p":"0.002"},{"name":"PFS","value":7.7,"unit":"months","hr":0.61,"hr_ci95":[0.48,0.76],"p":"0.002"},{"name":"ORR","value":55.7,"unit":"percent"}],"summary":"Median OS 18.3 months. HR 0.6 (95% CI 0.46–0.74). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-05T16:45:00-05:00","status":"released"}},{"abstract_id":"2025-9024","abstract_number":"9024","doi":"10.1200/JCO.2025.44.17_suppl.9024","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"20:30","room":"Hall B1"},"title":"Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-306","authors":[{"name":"J. Brahmer","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"F. Andre","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Mayo Clinic","is_presenter":false},{"name":"H. Rugo","affiliation":"Cleveland Clinic","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-306","nct_id":"NCT40970964","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":26.3,"unit":"months","hr":0.74,"hr_ci95":[0.63,0.85],"p":"<0.001"},{"name":"PFS","value":10.7,"unit":"months","hr":0.71,"hr_ci95":[0.65,0.88],"p":"<0.001"},{"name":"ORR","value":42,"unit":"percent"}],"summary":"Median OS 26.3 months. HR 0.74 (95% CI 0.63–0.85). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-03T20:30:00-05:00","status":"released"}},{"abstract_id":"2025-9186","abstract_number":"9186","doi":"10.1200/JCO.2025.44.17_suppl.9186","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"14:00","room":"E450"},"title":"IMpower-625: Tecentriq (atezolizumab) neoadjuvant in NSCLC","authors":[{"name":"N. Rizvi","affiliation":"Institut Gustave Roussy","is_presenter":true},{"name":"P. Schmid","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"S. Modi","affiliation":"Mayo Clinic","is_presenter":false},{"name":"S. Antonia","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"S. Tolaney","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-625","nct_id":"NCT09752862","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":26.3,"unit":"months","hr":0.83,"hr_ci95":[0.74,0.92],"p":"0.03"},{"name":"PFS","value":11.4,"unit":"months","hr":0.82,"hr_ci95":[0.7,0.89],"p":"0.03"},{"name":"ORR","value":48.8,"unit":"percent"}],"summary":"Median OS 26.3 months. HR 0.83 (95% CI 0.74–0.92). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-04T14:00:00-05:00","status":"released"}},{"abstract_id":"2025-9568","abstract_number":"9568","doi":"10.1200/JCO.2025.44.17_suppl.9568","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Clinical Science Symposium","title":"Clinical Science Symposium: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"18:45","room":"Arie Crown Theater"},"title":"FLAURA-324: Tagrisso (osimertinib) maintenance in NSCLC","authors":[{"name":"J. Cortes","affiliation":"Karolinska Institute","is_presenter":true},{"name":"M. Krop","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"H. Rugo","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"N. Rizvi","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-324","nct_id":"NCT29521655","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"standard of care","endpoints":[{"name":"OS","value":27.7,"unit":"months","hr":0.73,"hr_ci95":[0.63,0.83],"p":"0.03"},{"name":"PFS","value":9.7,"unit":"months","hr":0.74,"hr_ci95":[0.67,0.84],"p":"0.03"},{"name":"ORR","value":64.3,"unit":"percent"}],"summary":"Median OS 27.7 months. HR 0.73 (95% CI 0.63–0.83). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-03T18:45:00-05:00","status":"released"}},{"abstract_id":"2025-9949","abstract_number":"9949","doi":"10.1200/JCO.2025.44.17_suppl.9949","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-05","time_local":"15:00","room":"S100A"},"title":"Long-term follow-up of Enhertu maintenance for NSCLC: DESTINY-Breast-969","authors":[{"name":"G. Curigliano","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":true},{"name":"M. Reck","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"J. Cortes","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-969","nct_id":"NCT05601135","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":20.2,"unit":"months","hr":0.7,"hr_ci95":[0.59,0.81],"p":"0.002"},{"name":"PFS","value":8.5,"unit":"months","hr":0.75,"hr_ci95":[0.6,0.82],"p":"0.002"},{"name":"ORR","value":60.5,"unit":"percent"}],"summary":"Median OS 20.2 months. HR 0.7 (95% CI 0.59–0.81). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-05T15:00:00-05:00","status":"released"}},{"abstract_id":"2025-9699","abstract_number":"9699","doi":"10.1200/JCO.2025.44.17_suppl.9699","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"16:00","room":"Hall B1"},"title":"CheckMate-935: Opdivo (nivolumab) adjuvant in NSCLC","authors":[{"name":"R. Herbst","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"M. Krop","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-935","nct_id":"NCT03577406","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":17.5,"unit":"months","hr":0.65,"hr_ci95":[0.55,0.75],"p":"0.002"},{"name":"PFS","value":11.2,"unit":"months","hr":0.63,"hr_ci95":[0.52,0.73],"p":"0.002"},{"name":"ORR","value":56.6,"unit":"percent"}],"summary":"Median OS 17.5 months. HR 0.65 (95% CI 0.55–0.75). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-04T16:00:00-05:00","status":"released"}},{"abstract_id":"2025-9806","abstract_number":"9806","doi":"10.1200/JCO.2025.44.17_suppl.9806","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"16:15","room":"Arie Crown Theater"},"title":"FLAURA-17: Tagrisso (osimertinib) 3L+ in NSCLC","authors":[{"name":"H. Borghaei","affiliation":"University of Chicago","is_presenter":true},{"name":"M. Krop","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"S. Tolaney","affiliation":"Massachusetts General Hospital","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-17","nct_id":"NCT50269695","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":22.7,"unit":"months","hr":0.59,"hr_ci95":[0.5,0.68],"p":"<0.001"},{"name":"PFS","value":10.7,"unit":"months","hr":0.63,"hr_ci95":[0.47,0.72],"p":"<0.001"},{"name":"ORR","value":64.4,"unit":"percent"}],"summary":"Median OS 22.7 months. HR 0.59 (95% CI 0.5–0.68). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-03T16:15:00-05:00","status":"released"}},{"abstract_id":"2025-9251","abstract_number":"9251","doi":"10.1200/JCO.2025.44.17_suppl.9251","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-02","time_local":"16:45","room":"Arie Crown Theater"},"title":"Quality of life outcomes with Imfinzi in patients with NSCLC","authors":[{"name":"M.C. Garassino","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":true},{"name":"M. Krop","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"A. Spira","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"C. Saura","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-406","nct_id":"NCT24405522","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":16.9,"unit":"months","hr":0.56,"hr_ci95":[0.46,0.66],"p":"0.03"},{"name":"PFS","value":7.8,"unit":"months","hr":0.6,"hr_ci95":[0.43,0.68],"p":"0.03"},{"name":"ORR","value":64.1,"unit":"percent"}],"summary":"Median OS 16.9 months. HR 0.56 (95% CI 0.46–0.66). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-02T16:45:00-05:00","status":"released"}},{"abstract_id":"2025-9042","abstract_number":"9042","doi":"10.1200/JCO.2025.44.17_suppl.9042","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-04","time_local":"21:30","room":"S100A"},"title":"Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-179","authors":[{"name":"N. Rizvi","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":true},{"name":"M. Krop","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"S. Modi","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-179","nct_id":"NCT83096731","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":24.3,"unit":"months","hr":0.71,"hr_ci95":[0.6,0.82],"p":"0.03"},{"name":"PFS","value":7.8,"unit":"months","hr":0.71,"hr_ci95":[0.61,0.84],"p":"0.03"},{"name":"ORR","value":42.5,"unit":"percent"}],"summary":"Median OS 24.3 months. HR 0.71 (95% CI 0.6–0.82). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2025-09-04T21:30:00-05:00","status":"released"}},{"abstract_id":"2025-9538","abstract_number":"9538","doi":"10.1200/JCO.2025.44.17_suppl.9538","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-01","time_local":"15:45","room":"Hall B1"},"title":"Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-838","authors":[{"name":"S. Tolaney","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"H. Borghaei","affiliation":"Royal Marsden Hospital","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-838","nct_id":"NCT96596453","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"standard of care","endpoints":[{"name":"OS","value":29.2,"unit":"months","hr":0.74,"hr_ci95":[0.63,0.85],"p":"0.002"},{"name":"PFS","value":9.4,"unit":"months","hr":0.76,"hr_ci95":[0.61,0.83],"p":"0.002"},{"name":"ORR","value":41.1,"unit":"percent"}],"summary":"Median OS 29.2 months. HR 0.74 (95% CI 0.63–0.85). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2025-09-01T15:45:00-05:00","status":"released"}},{"abstract_id":"2025-9100","abstract_number":"9100","doi":"10.1200/JCO.2025.44.17_suppl.9100","meeting":"ESMO Congress","meeting_city":"Barcelona, Spain","meeting_year":2025,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2025-09-03","time_local":"14:30","room":"S406"},"title":"Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-725","authors":[{"name":"S. Antonia","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"H. Borghaei","affiliation":"Karolinska Institute","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Karolinska Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-725","nct_id":"NCT78132096","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":16.1,"unit":"months","hr":0.76,"hr_ci95":[0.67,0.85],"p":"0.08"},{"name":"PFS","value":10.8,"unit":"months","hr":0.8,"hr_ci95":[0.67,0.82],"p":"0.08"},{"name":"ORR","value":48.8,"unit":"percent"}],"summary":"Median OS 16.1 months. HR 0.76 (95% CI 0.67–0.85). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2025-09-03T14:30:00-05:00","status":"released"}}]}